Juvaris BioTherapeutics News
Most Popular Juvaris BioTherapeutics Story
Juvaris completes $25M close of series B
Adjuvant vaccines developer Juvaris BioTherapeutics has completed the first close of a Series B round. The Burlingame, CA-based company says it will use the capital to advance its technology platform... Read more...
Latest Headlines
- September 17, 2009
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
